ATM is approved for the treatment of rheumatoid arthritis (RA) and a phase I study found ATM to be well tolerated in patients with advanced NSCLC, ovarian cancer and pancreatic cancer (Mansfield et al., 2013). This evidence concerns the gene ATM and rheumatoid arthritis.